Vascular endothelial growth factor (VEGF) immunohistochemistry (IHC) assessed angiogenic activity at the tumour-physis interface.<h4>Results</h4>Pulmonary metastases were present in 22% at diagnosis and in 50% (16/32) by last follow-up. Here, VEGFA is linked to neoplasm.